整合素和金属蛋白酶域33基因V4多态性与支气管哮喘易患性关系的Meta分析

V4 Polymorphisms in the ADAM33 Gene and Liability of Bronchial Asthma: A Meta-analysis on Their Relationship

目的探讨整合素和金属蛋白酶域33(ADAM33)基因V4(rs2787094 G>C)多态性与支气管哮喘易患性的关系。方法检索中国生物医学文献数据库(CBM)、维普网、万方数据知识服务平台、中国知网(CNKI)、PubMed、EMBase、Google学术、Web of Science等电子数据库,检索范围均从建库至2013年8月,筛选符合纳入标准的文献,由两位研究员进行数据收集、提取。采用Stata 12.0软件进行Meta分析。结果最终共纳入8篇文献,均为病例对照研究,共包括2 128例支气管哮喘患者(病例组)和3 134例健康对照者(对照组)。Meta分析结果显示:在等位基因模型和显性模型中,ADAM33基因V4多态性与支气管哮喘易患性有关〔G与C:OR=1.58,95%CI(1.14,2.18),P=0.006;GG+GC与CC:OR=1.42,95%CI(1.25,1.60),P=0.000〕。亚组分析结果显示:对照组来源为普通人群时,在等位基因模型和显性模型中,ADAM33基因V4多态性与支气管哮喘易患性有关〔G与C:OR=1.58,95%CI(1.06,2.35),P=0.024;GG+GC与CC:OR=1.40,95%CI(1.22,1.60),P=0.000〕;对照组来源为医院人群时,在等位基因模型中,ADAM33基因V4多态性与支气管哮喘易患性无关〔OR=1.57,95%CI(0.73,3.37),P=0.244〕,在显性模型中,ADAM33基因V4多态性与支气管哮喘易患性有关〔OR=1.53,95%CI(1.12,2.08),P=0.000〕。采用聚合酶链反应-限制性片段长度多态性检测法(PCR-RFLP)进行检测时,在等位基因模型和显性模型中,ADAM33基因V4多态性与支气管哮喘易患性有关〔G与C:OR=2.21,95%CI(1.44,3.40),P=0.001;GG+GC与CC:OR=2.29,95%CI(1.88,2.78),P=0.000〕;采用其他检测方法时,在等位基因模型和显性模型中,ADAM33基因V4多态性与支气管哮喘易患性无关〔G与C:OR=1.07,95%CI(0.94,1.21),P=0.314;GG+GC与CC:OR=1.02,95%CI(0.87,1.20),P=0.769〕。结论 ADAM33基因V4多态性可能与支气管哮喘易患性增加有关,有可能作为早期诊断支气管哮喘的分子标志物。

ObjectiveToevaluatetherelationshipbetweenV4（rs2787094G〉C）polymorphismsinadisintegrin and metalloproteinase 33 （ADAM33） gene and liability of bronchial asthma .Methods Relevant studies were searched for in CBM, VIP, Wanfang, CNKI, PubMed, EMBase, Google Scholar, and Web of Science databases from their inception to Au-gust 2013.Data was collected and extracted by two researchers , and Stata 12.0 software was used to performed a Meta -analy-sis.Results A total of 8 literatures of randomized controlled studies were included , including 2 128 asthma patients and 3 134 healthy controls.By Meta-analysis, in allele and dominant models, ADAM33 gene V4 polymorphism was related to liability of bronchial asthma 〔G vs.C： OR=1.58, 95%CI （1.14, 2.18）, P=0.006; GG＋GC vs.CC： OR=1.42, 95%CI （1.25, 1.60）, P=0.000〕.By subgroup analysis, when controls were general people , in allele and dominant models, ADAM33 gene V4 polymorphism was related to liability of bronchial asthma 〔G vs.C： OR=1.58, 95%CI （1.06, 2.35）, P=0.024; GG＋GC vs.CC： OR=1.40, 95%CI （1.22, 1.60）, P=0.000〕; When control group were from hospital , in allele models, ADAM33 gene V4 polymorphism was not related to liability of bronchial asthma 〔OR=1.57, 95%CI （0.73, 3.37）, P=0.244〕, and in dominant models , ADAM33 gene V4 polymorphism was related to liability of bronchial asthma 〔OR=1.53, 95%CI （ 1.12, 2.08 ）, P =0.000〕. By polymerase chain reaction - restricted fragment length polymorphisms＆amp;nbsp;（ PCR-RFLP） , in allele and dominant models , ADAM33 gene V4 polymorphism was related to liability of bronchial asthma 〔G vs.C： OR=2.21, 95%CI （1.44, 3.40）, P =0.001; GG ＋GC vs.CC： OR =2.29, 95%CI （1.88, 2.78）, P =0.000〕.By other detection methods , in allele and dominant models , ADAM33 gene V4 polymorphism was not related to liabil-ity of bronchial asthma 〔G vs.C： OR=1.07, 95%CI （0.94, 1.21）, P=0.314; GG＋GC vs.CC： OR=1.02, 95%CI （0.87, 1.20）, P=0.769〕.Conclusion ADAM33 gene V4 polymorphism, probably related to liability of bronchial asthma , can be used as a molecular marker for early diagnosis of bronchial asthma .